Clinical Trials Browser

Recurrence × PHI-101 × Other hematologic neoplasm × Clear all

NCT04842370 2021-04-20

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Phase 1 Unknown

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute